SCYNEXIS, Inc.
SCYX Healthcare Drug Manufacturers Specialty & Generic
SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024. In the quarter to June 2026, revenue fell 8.56%, EPS grew 156.3% and free cash flow fell 98.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SCYX
SCYNEXIS, Inc. (SCYX) P/E ratio
SCYNEXIS, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 3.9× (September 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 1.6× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 35 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RMTI Rockwell Medical, Inc. compare | n/m |
| SCYX SCYNEXIS, Inc. | n/m |
| TXMD TherapeuticsMD, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| TLPH Talphera, Inc. compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | 0.2× |
| INCR InterCure Ltd. compare | 8.8× |
| ZYBT Zhengye Biotechnology Holding Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)